Epidemiology of molecular probes in Xpert MTB/RIF assay in Khyber Pakhtunkhwa, Pakistan.


Journal

Archives of microbiology
ISSN: 1432-072X
Titre abrégé: Arch Microbiol
Pays: Germany
ID NLM: 0410427

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 28 07 2020
accepted: 13 02 2021
revised: 24 01 2021
pubmed: 1 3 2021
medline: 30 6 2021
entrez: 28 2 2021
Statut: ppublish

Résumé

Regardless of a plethora of advanced diagnostics, TB and drug resistance remains a principal killer. We proposed gold nanoparticles (AuNPs) attached with probes to enhance the efficiency of GeneXpert MTB/RIF assay instead of conventional dye probes for molecular detection. A total of 15,000 samples were collected from TB suspects and subjected to Xpert MTB/RIF assay, where 6800 (45.3%) were detected as MTB positive, 280 (4.3%) were detected to harbor mutations in the RRDR, while invalid /errors were found in 690 (4.6%) cases. The mutations were detected by probe E, 199 (71.1%), while probes B and D, 30 and 26 (10% and 9%), respectively. In the Xpert MTB/RIF Assay were found mutations picked by probes E and B codons 529-533 (71%) and 512-518 (10%), respectively. The fast-rising works of TB nano-diagnostics, of Xpert probes, may improve by the applications of gold nanoparticle probes.

Identifiants

pubmed: 33640990
doi: 10.1007/s00203-021-02242-5
pii: 10.1007/s00203-021-02242-5
doi:

Substances chimiques

Antibiotics, Antitubercular 0
Codon 0
Molecular Probes 0
Gold 7440-57-5
Rifampin VJT6J7R4TR

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2249-2256

Références

Ardizzoni E, Fajardo E, Saranchuk P et al (2015) Implementing the Xpert® MTB/RIF diagnostic test for tuberculosis and rifampicin resistance: outcomes and lessons learned in 18 countries. PLoS ONE 10:e0144656. https://doi.org/10.1371/journal.pone.0144656
doi: 10.1371/journal.pone.0144656 pubmed: 26670929 pmcid: 4682866
Baptista PV, Koziol-Montewka M, Paluch-Oles J et al (2006) Gold-nanoparticle-probe-based assay for rapid and direct detection of Mycobacterium tuberculosis DNA in clinical samples. Clin Chem 52:1433–1434. https://doi.org/10.1373/clinchem.2005.065391
doi: 10.1373/clinchem.2005.065391 pubmed: 16798971
Boehme CC, Nabeta P, Hillemann D et al (2010) Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363:1005–1015. https://doi.org/10.1056/NEJMoa0907847
doi: 10.1056/NEJMoa0907847 pubmed: 20825313 pmcid: 2947799
Brossier F, Veziris N, Jarlier V, Sougakoff W (2009) Performance of MTBDR plus for detecting high/low levels of Mycobacterium tuberculosis resistance to isoniazid. Int J Tuberc Lung Dis 13:260–265
pubmed: 19146757
Chiang C-Y, Van Weezenbeek C, Mori T, Enarson DA (2013) Challenges to the global control of tuberculosis. Respirol Carlton Vic 18:596–604. https://doi.org/10.1111/resp.12067
doi: 10.1111/resp.12067
Coovadia YM, Mahomed S, Pillay M et al (2013) Rifampicin mono-resistance in Mycobacterium tuberculosis in KwaZulu-Natal, South Africa: a significant phenomenon in a high prevalence TB-HIV region. PLoS ONE 8:e77712. https://doi.org/10.1371/journal.pone.0077712
doi: 10.1371/journal.pone.0077712 pubmed: 24223122 pmcid: 3819362
Creswell J, Codlin AJ, Andre E et al (2014) Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC Infect Dis 14:2. https://doi.org/10.1186/1471-2334-14-2
doi: 10.1186/1471-2334-14-2 pubmed: 24383553 pmcid: 3898850
Elghanian R, Storhoff JJ, Mucic RC et al (1997) Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles. Science 277:1078–1081
doi: 10.1126/science.277.5329.1078
El-Samadony H, Althani A, Tageldin MA, Azzazy HME (2017) Nanodiagnostics for tuberculosis detection. Expert Rev Mol Diagn 17:427–443. https://doi.org/10.1080/14737159.2017.1308825
doi: 10.1080/14737159.2017.1308825 pubmed: 28317400
Forli S, Huey R, Pique ME et al (2016) Computational protein–ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc 11:905–919. https://doi.org/10.1038/nprot.2016.051
doi: 10.1038/nprot.2016.051 pubmed: 27077332 pmcid: 4868550
Gidado M, Nwokoye N, Nwadike P et al (2018) Unsuccessful Xpert® MTB/RIF results: the Nigerian experience. Public Health Action 8:2–6. https://doi.org/10.5588/pha.17.0080
doi: 10.5588/pha.17.0080 pubmed: 29581936 pmcid: 5858060
Gous N, Scott LE, Khan S et al (2015) Diagnosing childhood pulmonary tuberculosis using a single sputum specimen on Xpert MTB/RIF at point of care. SAMJ South Afr Med J 105:1044–1048. https://doi.org/10.7196/samj.2015.v105i12.8585
doi: 10.7196/samj.2015.v105i12.8585
Huang H, Zhang Y, Li S et al (2018) Rifampicin resistance and multidrug-resistant tuberculosis detection using Xpert MTB/RIF in Wuhan, China: a retrospective study. Microb Drug Resist 24:675–679. https://doi.org/10.1089/mdr.2017.0114
doi: 10.1089/mdr.2017.0114 pubmed: 29053085
Kent PT, Kubica GP (1985) Public health mycobacteriology: a guide for the level III laboratory. Public Health Service, Centers for Disease Control, US Department of Health and Human Services
Lawn SD, Nicol MP (2011) Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol 6:1067–1082. https://doi.org/10.2217/fmb.11.84
doi: 10.2217/fmb.11.84 pubmed: 21958145 pmcid: 3252681
Mao X, Xu H, Zeng Q et al (2009) Molecular beacon-functionalized gold nanoparticles as probes in dry-reagent strip biosensor for DNA analysis. Chem Commun. https://doi.org/10.1039/B822582F
doi: 10.1039/B822582F
Marlowe EM, Novak-Weekley SM, Cumpio J et al (2011) Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J Clin Microbiol 49:1621–1623. https://doi.org/10.1128/JCM.02214-10
doi: 10.1128/JCM.02214-10 pubmed: 21289151 pmcid: 3122817
Matsishin M, Rachkov A, Lopatynskyi A et al (2017) Selective amplification of SPR biosensor signal for recognition of rpoB gene fragments by use of gold nanoparticles modified by thiolated DNA. Nanoscale Res Lett 12:252. https://doi.org/10.1186/s11671-017-2031-y
doi: 10.1186/s11671-017-2031-y pubmed: 28381076 pmcid: 5380648
Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ (1996) A DNA-based method for rationally assembling nanoparticles into macroscopic materials. Nature 382:607–609. https://doi.org/10.1038/382607a0
doi: 10.1038/382607a0 pubmed: 8757129
Ochang EA, Udoh UA, Emanghe UE et al (2016) Evaluation of rifampicin resistance and 81-bp rifampicin resistant determinant region of rpoB gene mutations of Mycobacterium tuberculosis detected with XpertMTB/Rif in Cross River State, Nigeria. Int J Mycobacteriol 5:S145–S146. https://doi.org/10.1016/j.ijmyco.2016.09.007
doi: 10.1016/j.ijmyco.2016.09.007 pubmed: 28043515
Ocheretina O, Escuyer VE, Mabou M-M et al (2014) Correlation between genotypic and phenotypic testing for resistance to rifampin in Mycobacterium tuberculosis clinical isolates in Haiti: investigation of cases with discrepant susceptibility results. PLoS ONE 9:e90569. https://doi.org/10.1371/journal.pone.0090569
doi: 10.1371/journal.pone.0090569 pubmed: 24599230 pmcid: 3944071
Organization WH (2013) Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update. World Health Organization, Geneva
Organization WH and others (2016) WHO treatment guidelines for drug-resistant tuberculosis 2016 update. WHO, Geneva
Pai M, Minion J, Sohn H et al (2009) Novel and improved technologies for tuberculosis diagnosis: progress and challenges. Clin Chest Med 30:701–716. https://doi.org/10.1016/j.ccm.2009.08.016
doi: 10.1016/j.ccm.2009.08.016 pubmed: 19925962
Piatek AS, Tyagi S, Pol AC et al (1998) Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis. Nat Biotechnol 16:359–363. https://doi.org/10.1038/nbt0498-359
doi: 10.1038/nbt0498-359 pubmed: 9555727
Piatek AS, Telenti A, Murray MR et al (2000) Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother 44:103–110
doi: 10.1128/AAC.44.1.103-110.2000
Pinyopornpanish K, Chaiwarith R, Pantip C et al (2015) Comparison of Xpert MTB/RIF assay and the conventional sputum microscopy in detecting Mycobacterium tuberculosis in Northern Thailand. Tuberc Res Treat. https://www.hindawi.com/journals/trt/2015/571782/ . Accessed 4 Jul 2018
Reddy R, Alvarez-Uria G (2017) Molecular epidemiology of rifampicin resistance in Mycobacterium tuberculosis using the GeneXpert MTB/RIF assay from a rural setting in India. J Pathog. https://www.hindawi.com/journals/jpath/2017/6738095/ . Accessed 4 Jan 2021
Shan Y, Xu J-J, Chen H-Y (2009) Distance-dependent quenching and enhancing of electrochemiluminescence from a CdS: Mn nanocrystal film by Au nanoparticles for highly sensitive detection of DNA. Chem Commun Camb Engl. https://doi.org/10.1039/b821049g
doi: 10.1039/b821049g
Sharma N, Khanna A, Chandra S et al (2019) Partnership in tuberculosis control through involvement of pharmacists in Delhi: an exploratory operational research study. Indian J Pharmacol 51:168–172. https://doi.org/10.4103/ijp.IJP_300_18
doi: 10.4103/ijp.IJP_300_18 pubmed: 31391684 pmcid: 6644184
Singh N, Dahiya B, Radhakrishnan VS et al (2018) Detection of Mycobacterium tuberculosis purified ESAT-6 (Rv3875) by magnetic bead-coupled gold nanoparticle-based immuno-PCR assay. Int J Nanomedicine 13:8523–8535. https://doi.org/10.2147/IJN.S181052
doi: 10.2147/IJN.S181052 pubmed: 30587975 pmcid: 6296691
Tyagi S, Kramer FR (1996) Molecular beacons: probes that fluoresce upon hybridization. Nat Biotechnol 14:303–308. https://doi.org/10.1038/nbt0396-303
doi: 10.1038/nbt0396-303 pubmed: 9630890
WHO (2008) Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis. World Health Organization, Geneva
WHO (2014) WHO policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. WHO, Geneva
WHO (2017) Global tuberculosis report 2017. World Health Organization, Geneva
World Health Organization (2013) Global tuberculosis report 2013. WHO, Geneva
Yue J, Shi W, Xie J et al (2003) Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from China. J Clin Microbiol 41:2209–2212
doi: 10.1128/JCM.41.5.2209-2212.2003
Zaw MT, Emran NA, Lin Z (2018) Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis. J Infect Public Health 11:605–610. https://doi.org/10.1016/j.jiph.2018.04.005
doi: 10.1016/j.jiph.2018.04.005 pubmed: 29706316

Auteurs

Anwar Sheed Khan (AS)

Provincial Tuberculosis Reference, Laboratory Hayatabad Medical Complex, Peshawar, Pakistan.

Muhammad Tahir Khan (MT)

Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan. muhammad.tahir8@imbb.uol.edu.pk.

Sajid Ali (S)

Provincial Tuberculosis Reference, Laboratory Hayatabad Medical Complex, Peshawar, Pakistan.

Taj Ali Khan (TA)

Department of Microbiology, Kohat University of Science and Technology, Kohat, Pakistan.

Muhammad Qasim (M)

Department of Microbiology, Kohat University of Science and Technology, Kohat, Pakistan.

Arif Malik (A)

Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.

Sajid Ali (S)

Department of Biotechnology, Abdul Wali Khan University, Mardan, Pakistan.

Wasim Sajjad (W)

State Key Laboratory of Cryospheric Science, Northwest Institute of Eco-Environment and Resources, Chinese Academy of Sciences, Lanzhou, 7300000, China.

Qurrat Ul Ain (QU)

Department of Microbiology, Quaid-I- Azam University, Islamabad, Pakistan.

Muhammad Irfan (M)

College of Dentistry, Department of Oral Biology, University of Florida, Gainesville, FL, 32610, USA. irfanmuhammad@ufl.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH